JKT:KLBF

PT Kalbe Farma Tbk. · JKT · Healthcare · IDR · FY for 2025

Figures on this page computed 2026-11-08 13:29 UTC

Last close

n/aIDR

Market data

9.4xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
IDR
- computed
- Computed from the filing for 2025
18.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
10.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
7.0%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.01Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
4.8%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
IDR
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

All from 100

lens 2 of 9

Sales

182

2016-12-31 to 2025-12-31100 at the start182

Sales: 100.00 on 2016-12-31 to 182.33 on 2025-12-31, up 82%.

Profit

159

2016-12-31 to 2025-12-31100 at the start159

Profit: 100.00 on 2016-12-31 to 159.37 on 2025-12-31, up 59%.

Shares in issue

97.1

2016-12-31 to 2025-12-31100 at the start97.1

Shares in issue: 100.00 on 2016-12-31 to 97.12 on 2025-12-31, down 3%.

Sales is at 182, Profit is at 159, Shares in issue is at 97, against 100 in 2016.

Sales is at 182, Profit is at 159, Shares in issue is at 97, against 100 in 2016.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 100182
Source
computed
Statement
income
Fiscal year
2025
Reported in
IDR
Profit, where the first year is 100159
Source
computed
Statement
income
Fiscal year
2025
Reported in
IDR
Shares in issue, where the first year is 10097
Source
computed
Statement
income
Fiscal year
2025
Reported in
IDR